Intellia Therapeutics (NTLA) Return on Invested Capital (2016)

Intellia Therapeutics (NTLA) reported Return on Invested Capital of 0.0% for Q3 2016, up 46.03% quarter-over-quarter from 0.0% in Q2 2016.

Intellia Therapeutics (NTLA) Return on Invested Capital (2016) Analysis & Trends

Intellia Therapeutics (NTLA) has 1 years of Return on Invested Capital data on file, last reported at 0.0% in Q3 2016.

Return on Invested Capital for Q3 2016 came in at 0.0%, changed N/A year-over-year; the trailing twelve-month figure through Sep 2016 was 0.0% (changed N/A YoY), and the FY2015 annual result was 0.02%, changed N/A from the prior year.
Return on Invested Capital climbed to 0.0% in Q3 2016 per NTLA's latest filing, from 0.0% in the prior quarter.
Over five years, Return on Invested Capital peaked at 0.01% in Q1 2016 and troughed at 0.0% in Q2 2016.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROIC (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	0.01%
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-0.01%
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-0.01%
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	0.00%
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Intellia Therapeutics	1.86 Bn	1.86 Bn	-	-

Download Data